title: Chronic pharmacological activation of P2Y13 receptor in mice decreases HDL-cholesterol level by increasing hepatic HDL uptake and bile acid secretion.
abstract: High level of high-density lipoprotein cholesterol (HDL-cholesterol) is inversely correlated to the risk of atherosclerotic cardiovascular disease. The protective effect of HDL is mostly attributed to their metabolic functions in reverse cholesterol transport (RCT), a process whereby excess cell cholesterol is taken up from peripheral cells and processed in HDL particles, and is later delivered to the liver for further metabolism and bile excretion. We have previously demonstrated that P2Y13 receptor is critical for RCT and that intravenous bolus injection of cangrelor (AR-C69931MX), a partial agonist of P2Y13 receptor, can stimulate hepatic HDL uptake and subsequent lipid biliary secretion without any change in plasma lipid levels. In the present study, we investigated the effect of longer-term treatment with cangrelor on lipoprotein metabolism in mice. We observed that continuous delivery of cangrelor at a rate of 35μg/day/kg body weight for 3days markedly decreased plasma HDL-cholesterol level, by increasing the clearance of HDL particles by the liver. These effects were correlated to an increase in the rate of biliary bile acid secretion. An increased expression of SREBP-regulated genes of cholesterol metabolism was also observed without any change of hepatic lipid levels as compared to non-treated mice. Thus, 3-day cangrelor treatment markedly increases the flux of HDL-cholesterol from the plasma to the liver for bile acid secretion. Taken together our results suggest that P2Y13 appears a promising target for therapeutic intervention aimed at preventing or reducing cardiovascular risk.
authors.affiliation: INSERM, UMR 1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, 31000, France.
authors.forename: Nizar
authors.initials: N
authors.lastname: Serhan
authors.forename: Cendrine
authors.initials: C
authors.lastname: Cabou
authors.forename: Céline
authors.initials: C
authors.lastname: Verdier
authors.forename: Laeticia
authors.initials: L
authors.lastname: Lichtenstein
authors.forename: Nicole
authors.initials: N
authors.lastname: Malet
authors.forename: Bertrand
authors.initials: B
authors.lastname: Perret
authors.forename: Muriel
authors.initials: M
authors.lastname: Laffargue
authors.forename: Laurent O
authors.initials: LO
authors.lastname: Martinez
mesh_terms: D000249:Adenosine Monophosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001647:Bile Acids and Salts / Q000378:metabolism*; D001692:Biological Transport / Q000187:drug effects; D008076:Cholesterol, HDL / Q000378:metabolism*; D008075:Lipoproteins, HDL / Q000378:metabolism; D008099:Liver / Q000187:drug effects* / Q000378:metabolism*; D051379:Mice; D058912:Purinergic P2Y Receptor Agonists / Q000494:pharmacology; D018048:Receptors, Purinergic P2 / Q000378:metabolism*
chemical_list: D001647:Bile Acids and Salts; D008076:Cholesterol, HDL; D008075:Lipoproteins, HDL; C486689:P2ry13 protein, mouse; D058912:Purinergic P2Y Receptor Agonists; D018048:Receptors, Purinergic P2; D000249:Adenosine Monophosphate; C117446:cangrelor